Vaccines

Steven Varga, PhD, explains why infants and young children are so susceptible to severe respiratory syncytial virus (RSV) infections.

RSV expert Steven Varga, PhD, describes the failed vaccine trials that paved the way for the world's first respiratory syncytial virus (RSV) vaccine, as well as the innovations still needed to protect vulnerable populations against RSV infection.

The FDA has authorized GSK’s Arexvy (RSVPreF3 +AS01E) prevent lower respiratory tract disease (LRTD) caused by RSV in adults 60 years and older.

The vaccine efficacy of the Novavax’s NVX-CoV2373 was 79.5% in adolescents.

Panel moderator Rodney Rohde, PhD, notes that word choice is important and clinicians should emphasize the COVID-19 vaccine is not a live virus but is instead designed to challenge the immune system to protect against the virus.

Containing 20 serotypes, Pfizer's Prevnar 20 grants the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine.

An outbreak of the highly infectious measles virus has led American Samoa to declare a public health emergency.

The last week in April is World Immunization Week, and we're recapping the most recent and significant developments in infectious disease vaccines.

This study surveyed parents’ opinions on the risks of COVID-19 infection versus vaccination to determine how they affected the decision to vaccinate a child against COVID-19.

The CDC and FDA now recommend the Moderna and Pfizer-BioNTech mRNA bivalent COVID-19 vaccines be used for all vaccinations in the US.

Increased understanding of HCV protective immunity and HCV envelope glycoprotein structure and function may propel development of an HCV vaccine.

The FDA moved to harmonize primary and booster COVID-19 vaccine doses, deciding only the Moderna and Pfizer-BioNTech bivalent mRNA vaccines should be administered to individuals 6 months and older.

Post-COVID-19 conditions were more common in unvaccinated children than in children who had received at least 1 dose of a COVID-19 vaccine.

Catch up with this week's 5 most-read infectious disease stories.

Moderna announced new mRNA vaccine candidates to combat prevalent viruses, and is even developing their first-ever bacterial vaccine for Lyme disease.

Pfizer’s investigational RSV prefusion F protein−based vaccine (RSVpreF) was 81.8% effective at preventing medically attended severe RSV-associated lower respiratory tract illness in infants.

Despite high vaccination rates and intensive contact tracing and infection control protocols, an Omicron BA.5 outbreak occurred in Urumqi, China after the “zero-COVID policy” was lifted.

Nursing home residents 85 years and older or with comorbidities were the most susceptible to COVID-19 breakthrough infections.

This study examined the impact of COVID-19 vaccination and infection on the risk of cardiac and all-cause mortality in young people aged 12-29 years.

Because trust in science predicts willingness to get a COVID-19 vaccine, the results of this study have significant public health consequences.

A new study found negative expectations prior to COVID-19 vaccination were associated with more systemic adverse events in individuals receiving their second dose of a COVID-19 vaccine.

Using a pregnant rabbit model, investigators found a robust antigen-specific antibody response in pregnant rabbits against HIV and Zika virus.

A new study shows vaccination decreased the chances of developing the debilitating condition by nearly half.

The Wistar Institute’s Amelia Escolano, PhD, is developing a novel approach using sequential immunization to capture protection against multiple strains.

A new study suggests prioritizing administering the first dose a smallpox vaccine against mpox in cases where vaccine supplies are limited.